Medicare no longer covers Wegovy specifically for weight loss purposes, though coverage may still be available when prescribed for other medical conditions. Exception requests from doctors may provide ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

Trump administration has rejected Biden proposal to expand coverage Medicare currently covers Ozempic, Mounjaro solely for diabetes Wegovy, Zepbound not covered for weight loss Trump ...

Access remains limited to these effective but expensive drugs, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Between 2022 and 2023, Wegovy prescriptions in the Medi-Cal program jumped from 15,000 to 181,000, data from the U.S. Centers ...

Millions of Americans fighting obesity faced a setback last month when the Trump administration declined to allow Medicare and Medicaid to cover popular weight loss drugs like Wegovy and Zepbound.